Charles River Laboratories Announces First-Quarter 2025 Results

About this update from Charles River Laboratories International, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1245,"height":326,"url":"https://media.zenfs.com/en/business-wire.com/8ecfe7a23091ce704fd7cc087d30f3df"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ulE7k5.RH7913YOmN.Z.CA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI1MTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8ecfe7a23091ce704fd7cc087d30f3df","width":960,"height":251},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/BWTZZ2kaTFfTV3mNIm0KJg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02Mjg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/8ecfe7a23091ce704fd7cc087d30f3df","width":1200,"height":314}},"lazy":false},{"type":"text","content":"– First-Quarter Revenue of $984.2 Million –","length":43,"tagName":"p","attribs":{}},{"type":"text","content":"– First-Quarter GAAP Earnings per Share of $0.50 and Non-GAAP Earnings per Share of $2.34 –","length":91,"tagName":"p","attribs":{}},{"type":"text","content":"– Increases 2025 Guidance –","length":27,"tagName":"p","attribs":{}},{"type":"text","content":"– Repurchased $350 Million of Common Stock in First Quarter of 2025 –","length":69,"tagName":"p","attribs":{}},{"type":"text","content":"WILMINGTON, Mass., May 07, 2025--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2025. For the quarter, revenue was $984.2 million, a decrease of 2.7% from $1,011.6 million in the first quarter of 2024.","length":282,"tagName":"p"},{"type":"text","content":"The impact of foreign currency translation reduced reported revenue by 0.9%. Excluding this impact, revenue decreased 1.8% on an organic basis driven by declines in all three business segments.","length":193,"tagName":"p"},{"type":"text","content":"In the first quarter of 2025, the GAAP operating margin decreased to 7.6% from 12.5% in the first quarter of 2024. The GAAP decrease was primarily driven by lower revenue and higher amortization expense related to accelerated amortization of certain CDMO client relationships. On a non-GAAP basis, the first-quarter operating margin increased to 19.1% from 18.5%, driven primarily by the benefit of cost savings resulting from restructuring initiatives, partially offset by lower revenue.","length":488,"tagName":"p"},{"type":"text","con...

More updates from Charles River Laboratories International, Inc.